Results 151 to 160 of about 5,158 (194)

Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. [PDF]

JCO Precis Oncol
Saylor PJ, Otani K, Balza R, Ukleja J, Pleskow H, Fisher R, Kusaka E, Otani YS, Badusi PO, Smith MR, Meneely E, Olivier K, Lowe AC, Toner M, Maheswaran S, Haber DA, Yeap BY, Lee RJ, Miyamoto DT.   +18 more
europepmc   +1 more source

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. [PDF]

Cancer Immunol Res
Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, Bhatt RS, Sweeney CJ, Bubley GJ, Jacene HA, Taplin ME, Huang FW, Harshman LC, Fong L.   +25 more
europepmc   +1 more source

Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan. [PDF]

J Chin Med Assoc
Yao SF, Huang WJ, Wei TC, Wang YF, Lin KH, Hu LH, Ting CH, Lee TH, Yeh SH, Peng NJ.   +9 more
europepmc   +1 more source

Radium-223-dikloridi

, 2015
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Radium-223 chloride

Reactions Weekly, 2019
  +9 more sources

Radium-223-chloride

Reactions Weekly, 2017
  +8 more sources

Radium 223 chloride

Reactions Weekly, 2018
  +6 more sources

Radium-223 for the treatment of prostate cancer

Expert Opinion on Investigational Drugs, 2013
Bone metastases cause significant morbidity and mortality in castration-resistant prostate cancer (CRPC). Until recently, treatment options have been limited, but now six drugs are known to extend life expectancy, with docetaxel the current standard first-line cytotoxic therapy.
Shaista, Hafeez, Christopher, Parker
openaire   +2 more sources

Alphastrahler Radium-223-Dichlorid

Der Urologe, 2014
Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily ...
H. Heinzer, F. König, S. Klutmann
openaire   +1 more source